Is Laurus Labs overvalued or undervalued?

As of 22 August 2025, Laurus Labs' valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on its high valuation ratios, including a PE ratio of 93.10, an EV to EBITDA of 39.48, and a Price to Book Value of 10.59. Compared to peers, Laurus Labs stands out with a significantly higher PE ratio than Sun Pharma (34.36) and Divi's Lab (70.86), both of which are also categorized as expensive or very expensive. Given these metrics, Laurus Labs is considered overvalued in the current market environment. The company's return performance has been strong, with a year-to-date stock return of 45.69%, significantly outpacing the Sensex's 4.05% return, which may contribute to the elevated valuation. Nonetheless, the high ratios suggest that investors should exercise caution, as the stock may not be justified at its current price levels.